ACE and sarcopenia: The study conducted by Bashir et al. [27] in 2023 investigated the association between activin type I receptor polymorphisms (rs10783486 and rs2854464) and body composition in older individuals with sarcopenia, using data from the LACE randomized controlled trial, which investigated the effects of the Angiotensin-Converting Enzyme (ACE) inhibitor Perindopril and/or leucine on physical performance and muscle mass in older adults with sarcopenia [32].